‘Rise of the machines’: the next frontier in individualized medicine

Artificial intelligence (AI) andin silico models, in conjunction with the rapid adoption of mobile health (mHealth) technologies such as smart wearables, have the potential to revolutionize the monitoring, screening, and treatment of cardiovascular disease patients. Broadly speaking, AI and machine learning (ML) are predominantly statistical methods —learning from patient data to predict outcomes, with often little to no mechanistic understanding of the underlying processes. On the other hand, the nascent but rapidly developing field ofin silico models are mechanistic models —they use the underlying physics/chemistry to model the phenomenon of interest be that stroke and its treatment,1 heart failure,2 or cardiotoxicity.3 A typical example of anin silico model we use daily is the weather forecast —where the equations of weather formation are used in conjunction with previously collected data to make predictions on how the weather will develop. A synergistic use of both these statistical and mechanistic models will have the greatest value in aiding patient evaluation and treatment.
Source: Cardiovascular Research - Category: Cardiology Source Type: research